CalRx Biosimilar Insulin: California's Initiative to Enter the Insulin Market.

JAMA internal medicine（2023）

引用 0|浏览0

暂无评分

摘要

This viewpoint evaluates California's CalRx Biosimilar Insulin Initiative, which aims to address insulin affordability by offering less expensive alternatives to existing products, specifically targeting patients with insulin-dependent diabetes.

查看译文

关键词

calrx biosimilar insulin,insulin market,californias

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要